Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L S Schwartzberg

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Bone Marrow Transplantation|June 30, 1998
High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cellsC H Weaver, T Moss, L S Schwartzberg, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 13, 2000
Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanomaR O Dillman, S K Nayak, N M Barth, et al.
Critical Reviews in Oncology/Hematology|June 22, 2001
Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanomaR O Dillman, C DeLeon, L D Beutel, et al.
American Journal of Clinical Oncology|April 13, 1999
Adjuvant dose-intense chemotherapy with peripheral blood stem cell support in stage II-III breast cancer with five to nine involved axillary lymph nodesL S Schwartzberg, R Birch, K W Tauer, et al.
Cytotherapy|August 13, 2002
Breast tumor contamination of PBSC harvests: tumor depletion by positive selection of CD34(+) cellsJ Burgess, B Mills, M Griffith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2009
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimensK L Blackwell, M D Pegram, E Tan-Chiu, et al.
Transfusion|October 6, 1997
Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor: an analysis of 497 patientsC H Weaver, L S Schwartzberg, R Birch, et al.
Bone Marrow Transplantation|June 1, 1997
Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell contentC H Weaver, J Potz, J Redmond, et al.
Bone Marrow Transplantation|April 1, 1997
Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analysesC H Weaver, W H West, L S Schwartzberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 1, 1997
Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancerC H Weaver, L S Schwartzberg, R Birch, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Bone Marrow Transplantation|June 30, 1998
High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cellsC H Weaver, T Moss, L S Schwartzberg, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 13, 2000
Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanomaR O Dillman, S K Nayak, N M Barth, et al.
Critical Reviews in Oncology/Hematology|June 22, 2001
Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanomaR O Dillman, C DeLeon, L D Beutel, et al.
American Journal of Clinical Oncology|April 13, 1999
Adjuvant dose-intense chemotherapy with peripheral blood stem cell support in stage II-III breast cancer with five to nine involved axillary lymph nodesL S Schwartzberg, R Birch, K W Tauer, et al.
Cytotherapy|August 13, 2002
Breast tumor contamination of PBSC harvests: tumor depletion by positive selection of CD34(+) cellsJ Burgess, B Mills, M Griffith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2009
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimensK L Blackwell, M D Pegram, E Tan-Chiu, et al.
Transfusion|October 6, 1997
Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor: an analysis of 497 patientsC H Weaver, L S Schwartzberg, R Birch, et al.
Bone Marrow Transplantation|June 1, 1997
Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell contentC H Weaver, J Potz, J Redmond, et al.
Bone Marrow Transplantation|April 1, 1997
Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analysesC H Weaver, W H West, L S Schwartzberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 1, 1997
Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancerC H Weaver, L S Schwartzberg, R Birch, et al.
Pageof 3